Little Rock, ARNCT06995677Now EnrollingIRB Ready

Bladder Cancer Clinical Trial in Little Rock, AR

Access cutting-edge bladder cancer treatment through this phase 2 clinical trial at a research site in Little Rock. Study-provided care at no cost to qualified participants.

Sponsored by Tyra Biosciences, Inc

Quick Self-Assessment

See if you qualify for this Little Rock location

Preparing your pre-screening questions…

Expert Care in Little Rock

Access bladder cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related bladder cancer treatment provided free

Apply for This Little Rock Location

Check if you qualify for this bladder cancer clinical trial in Little Rock, AR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Little Rock

    Convenient for AR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Little Rock site if eligible
  4. 4Begin participation

About This Bladder Cancer Study in Little Rock

Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC

Sponsor: Tyra Biosciences, Inc

Who Can Participate

Inclusion Criteria

Participants age 18 and over of informed consent and willing and able to comply with all requires study procedures
Able to understand and given written informed consent
Participants with histologically confirmed low-grade NMIBC within 6 weeks prior to randomization with prior diagnostic biopsy/TURBT to confirm stage and grade and with at least 3 mm and no more than 12 mm total (1/2 a resectoscope loop to 2 loops, refer to Section 8.1.5) residual visible tumor as a marker lesion(s) left behind:
Ta low grade
T1 low grade
Participants must have intermediate risk NMIBC, defined as having any of the following characteristics (AUA Guidelines, 2024)
Recurrence within 1 year, LG Ta
Solitary LG Ta \>3cm
LG Ta, multifocal
Documented activating FGFR3 mutation or fusion (Appendix 4)
Have undergone bladder mapping and identification of visible marker lesion(s) within 6 weeks prior to randomization (refer to Inclusion Criterion #3)
No evidence of urothelial carcinoma of the upper urinary tract (confirmed by imaging) or prostatic urethra within 6 months of randomization
No prior BCG administration within 1 year of date of consent.
No intravesical chemotherapy within 8 weeks prior to C1D1.
Pathology consistent with pure urothelial carcinoma; if mixed histology, ensure that at least 80% of the sample is urothelial
Adequate bone marrow, liver, and renal function: b. Bone marrow function: i. Absolute neutrophil count (ANC) \> or = 1,500/mm3 ii. Platelet count \> or = 75,000/mm3 iii. /hemoglobin \> or = 10.0 g/dL e. Liver function: i.Total bilirubin \< or = ULN ii. Alanine aminotransferase (ALT) \< or = ULN iii. Aspartate aminotransferase (AST) \< or = ULN f. Renal function: i. estimated glomerular filtration rate \>60 mL/min calculated using the modification of diet in renal disease equation or CKD-EPI formula ii. Serum Phosphate level \< or = ULN prior to starting treatment g. Coagulation i. International normalized ratio (INR) \< or = 1.5 x ULN
Ability to swallow tablets
Participants (male and female) of child-bearing potential (including females who are post-menopausal for less than 1 year) must be willing to practice effective contraception while on treatment and be willing and able to continue contraception for 3 months (males) and 6 months (females) after the last dose of study treatment. Potential male participants should consider the potential impact of TYRA-300 on their ability to father a child and discuss options with the site study staff.
Potential participants who are positive for human immunodeficiency virus (HIV) must have a viral load below the limits of detection and on stable antiretroviral therapy for at least 3 months prior to C1D1. NOTE: some of the compounds in antiretroviral therapy may be on the prohibited medications list. Allowances will be made to ensure the participant's HIV treatment continues uninterrupted following a discussion with the Sponsor's medical monitor. A discussion of the impact of the antiretroviral therapy on TYRA- 300 needs to be discussed with the potential participant prior to C1D1.
Potential participants with chronic hepatitis B virus (HBV) infection with active disease should be on a suppressive antiviral therapy prior to C1D1.
Potential participants patients with a history of hepatitis C virus (HCV) infection should have completed curative antiviral treatment and must have a HCV viral load below the limit of quantification.
Potential participants with a history of HCV infection and on current treatment must have a HCV viral load below the limit of quantification

Exclusion Criteria

Presence of tumor in ureter or prostatic urethra:
Current or previous history of muscle invasive bladder cancer
Current or previous history of lymph node positive and/or metastatic bladder cancer
Evidence of pure squamous cell carcinoma, pure adenocarcinoma or pure undifferentiated carcinoma of the bladder
Currently receiving systemic cancer therapy (cytotoxic, immunotherapy, targeted)
Currently receiving treatment with a prohibited therapy (refer to Section 6.7.1)
Current or prior history of pelvic external beam radiotherapy
Current or history of receiving a prior FGFR inhibitor
Systemic immunotherapy within 6 months prior to randomization
Treatment with an investigational agent within 30 days or 5 half-lives from randomization, whichever is shorter; compounds with an unknown half-life will default to the 30 days.
Prior treatment with an intravesical agent within 8 weeks prior to C1D1
Current ongoing toxicity from previous therapy
Had major surgery within 4 weeks prior to C1D1
Any reason that in the view of the investigator, would substantially impair the ability of the participant to comply with study procedures and/or risk to the participant (i.e., uncontrolled diabetes)
Females who are pregnant, breastfeeding or planning to become pregnant within 6 months after the last dose of TYRA-300 and males who plan to father a child while enrolled in this study or within 3 months after the last dose of TYRA-300
Has impaired wound healing capacity
Serum phosphate levels above the upper limit of normal during screening
Any ocular condition likely to increase the risk of eye toxicity
Current evidence of central serous retinopathy or retinal pigmented epithelial detachment of any grade at time of baseline examination.
History of or current uncontrolled cardiovascular disease
Gastrointestinal disorders that will affect oral administration or absorption of TYRA-300
Known history of HIV infection, or active hepatitis B or C
History of a second primary malignancy within 3 years of signing ICF, except for nonmelanoma skin cancer and cured and active surveillance malignancies (i.e., prostate, breast) .
Known allergy to TYRA-300 or any excipients of the formulated product
Participants taking strong inhibitors and/or inducers of CYP3A4 enzyme
History of prolonged QT syndrome or baseline heart rate-corrected QT interval using Fridericia formula (QTcF) interval \>470 ms

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Little Rock?

Yes, this clinical trial (NCT06995677) has an active research site in Little Rock, AR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Bladder Cancer Treatment Options in Little Rock, AR

If you're searching for bladder cancer treatment options in Little Rock, AR, this clinical trial (NCT06995677) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Little Rock research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced bladder cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all bladder cancer clinical trials near you to find additional studies recruiting in your area.

More Bladder Cancer Trials in Little Rock, AR

See all bladder cancer clinical trials recruiting in Little Rock — not just this study.

Browse Bladder Cancer Trials in Little Rock →

Browse More Trials by Condition

Bladder Cancer TrialsGallbladder Cancer TrialsAlzheimers Disease TrialsADHD TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Little Rock?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Little Rock, AR